Open access
Open access
Powered by Google Translator Translator

Oncology – Lung

ASCO Guideline: Management of stage III non–small-cell lung cancer.

18 Jan, 2022 | 09:12h | UTC

Management of Stage III Non–Small-Cell Lung Cancer: ASCO Guideline – Journal of Clinical Oncology

 

RCT: Postoperative radiotherapy (PORT) did not increase disease-free survival compared with no PORT in patients with completely resected non-small-cell lung cancer and proven mediastinal N2 involvement.

8 Jan, 2022 | 22:38h | UTC

Postoperative radiotherapy versus no postoperative radiotherapy in patients with completely resected non-small-cell lung cancer and proven mediastinal N2 involvement (Lung ART): an open-label, randomised, phase 3 trial – The Lancet Oncology (link to abstract – $ for full-text)

Commentaries:

Postoperative Radiotherapy for Patients With Completely Resected Stage IIIA NSCLC and N2 Involvement – The ASCO Post

Post-Operative Radiotherapy Not Tied to Better Disease-Free Survival in NSCLC – MedPage Today (free registration required)

 

Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

8 Dec, 2021 | 09:47h | UTC

Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up – Annals of Oncology

 

Screening for Lung Cancer: CHEST Guideline and Expert Panel Report.

28 Nov, 2021 | 21:22h | UTC

Executive Summary: Screening for Lung Cancer: Chest Guideline and Expert Panel Report

Full Guideline: Screening for Lung Cancer: CHEST Guideline and Expert Panel Report

News Release: CHEST releases expert guidelines for lung cancer screening – Elsevier

Related:

USPSTF Statement: begin screening for lung cancer at age 50 years instead of 55 years for patients at risk

Meta-analysis: Lung cancer screening using low-dose computed tomography reduces lung cancer–specific mortality, albeit with a tradeoff of likely overdiagnosis

 

Commentary on Twitter

 

Making Sense of a Complex Disease: A Practical Approach to Managing Neuroendocrine Tumors.

9 Nov, 2021 | 01:04h | UTC

Making Sense of a Complex Disease: A Practical Approach to Managing Neuroendocrine Tumors – JCO Oncology Practice

 

Commentary on Twitter

 

RCT: Nivolumab vs. placebo in patients with relapsed malignant mesothelioma.

21 Oct, 2021 | 09:46h | UTC

Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial – The Lancet Oncology

 

Commentary on Twitter

 

Position statement on percutaneous ablation of non-small cell lung cancer and metastatic disease to the lungs.

8 Oct, 2021 | 10:12h | UTC

Society of Interventional Radiology Multidisciplinary Position Statement on Percutaneous Ablation of Non-small Cell Lung Cancer and Metastatic Disease to the Lungs – Journal of Vascular and Interventional Radiology

Commentary: Society of Interventional Radiology issues guidance for minimally invasive lung cancer treatments – Health Imaging

 

ESMO Guideline: Early and locally advanced non-small-cell lung cancer

14 Sep, 2021 | 08:42h | UTC

Early and locally advanced non-small-cell lung cancer: an update of the ESMO Clinical Practice Guidelines focusing on diagnosis, staging, systemic and local therapy – Annals of Oncology

 

Perspective: Toward personalized treatment approaches for non-small-cell lung cancer.

26 Aug, 2021 | 08:48h | UTC

Toward personalized treatment approaches for non-small-cell lung cancer – Nature Medicine (free for a limited period)

 

Commentary on Twitter

 

Surgery for lung cancer: postoperative changes and complications—what the Radiologist needs to know.

19 Aug, 2021 | 08:36h | UTC

Surgery for lung cancer: postoperative changes and complications—what the Radiologist needs to know – Insights into Imaging

 

Global, regional, and national burden of respiratory tract cancers and associated risk factors from 1990 to 2019: a systematic analysis for the Global Burden of Disease Study.

18 Aug, 2021 | 08:44h | UTC

Global, regional, and national burden of respiratory tract cancers and associated risk factors from 1990 to 2019: a systematic analysis for the Global Burden of Disease Study 2019 – The Lancet Respiratory Medicine

 

Commentary on Twitter (thread – click for more)

 

Randomized phase III trial of prophylactic cranial irradiation with or without hippocampal avoidance for small-cell lung cancer – “This trial provides the first clinical evidence that sparing the hippocampus during PCI in patients with SCLC better preserves cognitive function”.

13 Aug, 2021 | 08:54h | UTC

Randomized Phase III Trial of Prophylactic Cranial Irradiation With or Without Hippocampal Avoidance for Small-Cell Lung Cancer (PREMER): A GICOR-GOECP-SEOR Study – Journal of Clinical Oncology

 

Cohort study: Postdiagnosis smoking cessation linked to reduced risk for lung cancer progression and mortality.

29 Jul, 2021 | 11:12h | UTC

Postdiagnosis Smoking Cessation and Reduced Risk for Lung Cancer Progression and Mortality: A Prospective Cohort Study – Annals of Internal Medicine (link to abstract – $ for full-text)

Commentary: Never too late: Cancer centers push patients to quit smoking – STAT

Summary for Patients: Postdiagnosis Smoking Cessation and Reduced Risk for Lung Cancer Progression and Death

 

Commentary on Twitter

 

US Report: Death rates are declining for many common cancers, including lung cancer and melanoma.

15 Jul, 2021 | 09:11h | UTC

Report: Annual Report to the Nation on the Status of Cancer, Part 1: National Cancer Statistics – JNCI: Journal of the National Cancer Institute

News release: Annual Report to the Nation: Rapid decrease in lung cancer and melanoma deaths lead overall continued decline in cancer death rate – National Cancer Institute

Commentaries: Death rates are declining for many common cancers in the U.S., report finds – STAT AND Annual report to the nation: Rapid decrease in lung cancer and melanoma deaths – American Cancer Society

 

A deep learning algorithm can estimate malignancy risk of pulmonary nodules detected at low-dose screening CT.

24 May, 2021 | 08:21h | UTC

Deep Learning for Malignancy Risk Estimation of Pulmonary Nodules Detected at Low-Dose Screening CT – Radiology

Commentaries: AI predicts lung cancer risk – Radiological Society of North America AND AI Takes LDCT Further for Lung Cancer Prediction – Diagnostic Imaging

 

Commentary on Twitter

 

Perspective | New lung cancer screening guideline comes with many caveats

14 Mar, 2021 | 20:23h | UTC

New lung cancer screening guideline comes with many caveats – Lown Institute

Original Guideline: USPSTF Statement: begin screening for lung cancer at age 50 years instead of 55 years for patients at risk (article and commentaries)

 

USPSTF Statement: begin screening for lung cancer at age 50 years instead of 55 years for patients at risk

10 Mar, 2021 | 08:28h | UTC

Recommendation Statement: Screening for Lung Cancer – US Preventive Services Task Force

Editorials: Broadened Eligibility for Lung Cancer Screening: Challenges and Uncertainty for Implementation and Equity – JAMA AND Expanded Access to Lung Cancer Screening—Implementing Wisely to Optimize Health – JAMA Network Open AND New USPSTF Guidelines for Lung Cancer Screening: Better but Not Enough – JAMA Surgery AND The 2021 US Preventive Services Task Force Recommendation on Lung Cancer Screening: The More Things Stay the Same… – JAMA Oncology

 

Five-year outcomes from randomized, phase III trials: Nivolumab vs. Docetaxel in previously treated non–small-cell lung cancer

3 Mar, 2021 | 08:10h | UTC

Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non–Small-Cell Lung Cancer – Journal of Clinical Oncology

 

Commentary on Twitter

 

ASCO Guideline: Management of dyspnea in advanced cancer

24 Feb, 2021 | 02:10h | UTC

Management of Dyspnea in Advanced Cancer: ASCO Guideline – Journal of Clinical Oncology

 

Commentary on Twitter (thread – click for more)

 

Therapy for Stage IV Non–Small-Cell Lung Cancer With Driver Alterations: ASCO and OH (CCO) Joint Guideline Update

19 Feb, 2021 | 02:04h | UTC

Therapy for Stage IV Non–Small-Cell Lung Cancer With Driver Alterations: ASCO and OH (CCO) Joint Guideline Update – Journal of Clinical Oncology

 

RCT: Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%

18 Feb, 2021 | 02:34h | UTC

Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial – The Lancet

 

Commentary on Twitter

 

Radiation therapy for small-cell lung cancer: ASCO Guideline endorsement of an ASTRO Guideline

29 Jan, 2021 | 01:27h | UTC

Radiation Therapy for Small-Cell Lung Cancer: ASCO Guideline Endorsement of an ASTRO Guideline – Journal of Clinical Oncology

 

Stay Updated in Your Specialty

No spam, just news.